Table 4.
Quantitative 18F-FDG PET/CT findings for all patients and for each patient per group
| All included patients | Group 1 (12 (±2) weeks after prosthesis implantation) | Group 2 (12 (±2) months after prosthesis implantation) | p value* | |
|---|---|---|---|---|
| Number of patients | 20 | 10 | 10 | |
| SUVmax cranial anastomosis (mean±SD) | 4.7 [3.3–6.1] | 5.6 [4.1–6.1] | 3.8 [3.1–5.9] | .19 |
| SUVratio cranial anastomosis (mean±SD) | 2.3 [1.9–3.0] | 2.8 [2.3–3.2] | 2.0 [1.7–2.6] | .07 |
| EARL SUVmax cranial anastomosis (mean±SD) | 3.4 [2.8–4.1] | 3.8 [3.4–4.2] | 3.1 [2.5–3.6] | .08 |
| EARL SUVratio cranial anastomosis (mean±SD) | 1.7 [1.4–1.9] | 1.8 [1.7–2.0] | 1.5 [1.3–1.8] | .04 |
| SUVmax PHV median [IQR] | 5.5 [4.2–6.8] | 5.0 [4.1–5.7] | 6.3 [4.6–7.1] | .11 |
| SUVratio PHV median [IQR] | 2.6 [2.4–3.3] | 2.5 [2.4–2.8] | 2.9 [2.3–3.5] | .26 |
| EARL SUVmax PHV median [IQR] | 4.2 [3.4–5.0] | 4.1 [3.2–4.6] | 4.5 [3.7–5.6] | .21 |
| EARL SUVratio PHV median [IQR] | 2.1 [1.7–2.5] | 1.9 [1.7–2.2] | 2.3 [1.8–2.6] | .21 |
PHV, prosthetic heart valve; MBq/kg, Megabecquerel/kilograms; SUVmax, maximum standardized uptake value; SUVratio, standardized uptake value ratio (target-to-background ratio); EARL, European Association of nuclear medicine Research Ltd.
*Statistical difference between groups 1 and 2